Exploratory biomarker findings from cohort 2 of MODUL: An adaptable, phase 2, signal-seeking trial of fluoropyrimidine + bevacizumab ± atezolizumab maintenance therapy for BRAFwt metastatic colorectal cancer.
暂无分享，去创建一个
E. Van Cutsem | M. Ducreux | J. Tabernero | Alexander R. Abbas | A. Grothey | P. O'dwyer | M. Das Thakur | D. Arnold | H. Schmoll | N. Irahara | M. Perdicchio | A. Tahiri